Hereditary Angioedema Treatment Market Forecast: Long-Term Trends to 2032

The global hereditary angioedema (HAE) treatment market is witnessing rapid growth, fueled by rising awareness, innovative drug developments, and expanding patient populations worldwide. Hereditary angioedema is a rare genetic disorder that causes recurrent episodes of severe swelling, often affecting the limbs, face, intestinal tract, and airway. Timely diagnosis and advanced treatment options are crucial to managing this life-threatening condition effectively.

According to Fortune Business Insights, the hereditary angioedema treatment market was valued at USD 5.59 billion in 2024. The market is projected to grow from USD 6.53 billion in 2025 to USD 19.68 billion by 2032, exhibiting a CAGR of 17.1% during 2025-2032. In 2024, North America dominated the hereditary angioedema treatment market with a market share of 93.05%.

Top Companies in the Market

• CSL Behring
• Shire plc.
• Pharming Group NV
• BIOCRYST PHARMACEUTICALS, INC.
• Ionis Pharmaceuticals, Inc.
• Attune Pharmaceuticals
• Arrowhead Pharmaceuticals, Inc.
• Adverum
• Other prominent players

Market Drivers & Restraints

Market Drivers

• Increasing Disease Awareness: Enhanced awareness campaigns and improved diagnostic techniques have led to earlier identification and intervention, driving demand for effective treatments.
• Technological Advancements: Continuous R&D activities have led to the development of targeted therapies such as C1 esterase inhibitors and monoclonal antibodies that offer greater efficacy and safety profiles.
• Supportive Regulatory Approvals: Regulatory bodies like the FDA and EMA have been proactive in fast-tracking approvals for promising new therapies, accelerating their market availability.
• Growing Patient Support Programs: Pharmaceutical companies are investing in patient education and support programs, improving treatment adherence and patient outcomes.

Market Restraints

• High Cost of Treatment: The expensive nature of HAE therapies continues to pose affordability challenges, especially in emerging economies.
• Limited Access in Developing Countries: Lack of specialized healthcare infrastructure and limited insurance coverage impede market growth in low-income regions.
• Side Effects and Safety Concerns: Although new therapies are safer, some treatment options still present potential side effects, creating concerns among healthcare providers and patients.

Market Report Coverage

The comprehensive market report on hereditary angioedema treatment includes in-depth analysis of key trends, market size, competitive strategies, regional insights, and emerging opportunities. The report evaluates both historical data and forward-looking projections to offer a holistic understanding of the current market landscape and its expected growth trajectory.

Key Industry Development

In August 2018, Shire announced the U.S. Food and Drug Administration (FDA) approval for TAKHZYRO as a preventive treatment for hereditary angioedema. This milestone has played a pivotal role in expanding the preventive treatment landscape and has significantly improved the quality of life for patients suffering from HAE.

Market Competitive Landscape

The hereditary angioedema treatment market is highly competitive, with key players actively engaged in strategic collaborations, product launches, and research initiatives to strengthen their market presence. Companies are also focusing on developing next-generation therapies with improved efficacy, fewer side effects, and convenient administration methods, including subcutaneous and oral therapies.

Market Segments

By product type, the market is segmented into various drug classes. Among these, the C-1 esterase inhibitors segment is expected to lead the market during the forecast period. These inhibitors work by replacing the deficient or malfunctioning C1-inhibitor protein in patients, thereby preventing or mitigating angioedema attacks.

Key Product Segments Include:

• C1 Esterase Inhibitors
• Kallikrein Inhibitors
• Bradykinin B2 Receptor Antagonists
• Others

Prophylactic therapies and on-demand treatments both play crucial roles in the treatment paradigm, providing flexibility in managing acute episodes and preventing future attacks.

Market Regional Insights

The hereditary angioedema treatment market shows diverse growth patterns across various regions:

North America

North America holds the dominant market share due to high awareness levels, robust healthcare infrastructure, favorable reimbursement policies, and the early adoption of advanced therapies. The U.S. remains at the forefront of clinical research and drug approvals.

Europe

Europe follows closely behind, with significant growth driven by well-established healthcare systems, regulatory support, and increasing adoption of preventive treatments.

Asia-Pacific

The Asia-Pacific region is projected to witness the fastest growth, supported by improving healthcare infrastructure, growing awareness campaigns, and increasing healthcare expenditures across emerging economies such as China and India.

Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/industry-reports/hereditary-angioedema-treatment-market-100164 

Future Market Scope

The future of the hereditary angioedema treatment market looks promising, fueled by continuous innovations in gene therapy, RNA-based therapies, and novel biologics. Strategic partnerships, increasing clinical trials, and regulatory support will continue to unlock new growth avenues. Companies are actively exploring one-time curative therapies that aim to address the underlying genetic causes of HAE, potentially revolutionizing the treatment landscape in the coming years.

Furthermore, digital healthcare technologies, such as telemedicine platforms and remote patient monitoring, are expected to enhance disease management and patient compliance significantly. The integration of AI-driven diagnostic tools and precision medicine will further optimize personalized treatment approaches.

Conclusion

In summary, the hereditary angioedema treatment market is poised for sustained growth, driven by scientific advancements, regulatory approvals, and increasing patient awareness. As industry players continue to innovate and collaborate, patients worldwide can look forward to more effective, accessible, and life-changing therapies.

About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

Our reports are a blend of quantitative and qualitative analysis, aimed at helping businesses achieve sustainable growth. Our experienced analysts and consultants use leading research methodologies to provide comprehensive market assessments enriched with relevant data.

At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com